ResearcherUniversity of Mississippi Medical CenterActive in the last 2 years
Keli Xu
Matched on ORCID iD 0000-0001-5535-1076; OpenAlex author ID A5080769954; NIH RePORTER profile ID 11407654. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 0, last author 2)
- Trials
- 0
- Grants
- 1
- Labs led
- 1
- Collaborators
- 11
2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper, 1 grant
Papers 7
- NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.celrep.2026.117066↗
- Lfng-expressing centroacinar cell is a unique cell-of-origin for p53 deficient pancreatic cancer. Last author DOI 10.1038/s41388-024-03226-7↗
- Antagonism between Prdm16 and Smad4 specifies the trajectory and progression of pancreatic cancer. Co-author DOI 10.1083/jcb.202203036↗
- NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.celrep.2022.111623↗
- Pancreatic cancer triggers diabetes through TGF-β-mediated selective depletion of islet β-cells. Co-author DOI 10.26508/lsa.201900573↗
- TGIF1 functions as a tumor suppressor in pancreatic ductal adenocarcinoma. Co-author DOI 10.15252/embj.2018101067↗
- Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer. Last author DOI 10.1038/onc.2015.306↗
Grants 1
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Azeddine Atfi · 6 shared papers, 2019–2026 · strength 1.21
- Paper Lfng-expressing centroacinar cell is a unique cell-of-origin for p53 deficient pancreatic cancer. DOI 10.1038/s41388-024-03226-7↗
- Paper NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2026.117066↗
- Paper Antagonism between Prdm16 and Smad4 specifies the trajectory and progression of pancreatic cancer. DOI 10.1083/jcb.202203036↗
- Parash Parajuli · 5 shared papers, 2019–2026 · strength 0.84
- Paper NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2026.117066↗
- Paper Antagonism between Prdm16 and Smad4 specifies the trajectory and progression of pancreatic cancer. DOI 10.1083/jcb.202203036↗
- Paper NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2022.111623↗
- Mohammed Shawkat Razzaque · 5 shared papers, 2019–2026 · strength 0.84
- Paper NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2026.117066↗
- Paper Antagonism between Prdm16 and Smad4 specifies the trajectory and progression of pancreatic cancer. DOI 10.1083/jcb.202203036↗
- Paper NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2022.111623↗
- Creighton Friend · 3 shared papers, 2022–2026 · strength 0.62
- Paper NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2026.117066↗
- Paper Antagonism between Prdm16 and Smad4 specifies the trajectory and progression of pancreatic cancer. DOI 10.1083/jcb.202203036↗
- Paper NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2022.111623↗
- Eric G. Hurwitz · 3 shared papers, 2022–2026 · strength 0.62
- Paper NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2026.117066↗
- Paper Antagonism between Prdm16 and Smad4 specifies the trajectory and progression of pancreatic cancer. DOI 10.1083/jcb.202203036↗
- Paper NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2022.111623↗
- Gopalakrishnan Ramakrishnan · 2 shared papers, 2022–2026 · strength 0.46
- Wen-Cheng Chung · 1 shared paper, 2025 · strength 0.37
- Shubing Zhang · 1 shared paper, 2025 · strength 0.37
- Allyn Bryan · 1 shared paper, 2023 · strength 0.16
- S.-Y Zhang · 1 shared paper, 2016 · strength 0.10
- Zhe Wang · 1 shared paper, 2019 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.